Effect of Intravaginal Prasterone on Genitourinary Syndrome in Women in Menopause With Previous Breast Cancer or Currently Under Treatment With Endocrine Therapy for Breast Cancer With Aromatase Inhibitor +/- LHRHa

The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause and the effect on the quality of life, including sexual function and mood well-being, in women with Breast Cancer. A sample size of 95 patients will be needed to show that the proportion of women showing symptom improvement is greater than 50%. Subjects will be followed up at four weeks and twelve weeks of treatment. One and three-month outcomes will be provided after the end of treatment. Comparison between menopausal women with previous breast cancer that have finished hormonal therapy or with ER negative breast cancer and women currently under endocrine therapy with AIs will be performed.

开始日期2024-12-01

申办/合作机构

Istituto Europeo di Oncologia SRL

NCT05900661

/ Not yet recruiting临床2/3期IIT

The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders Undergoing ICSI : an Open Label Randomized Clinical Trial.

To evaulate the role of Myo-inositol, somatropin, DHEA on ICSI outcome in poor ovarian responder

开始日期2023-07-30

申办/合作机构

Beni-Suef University

NCT05562518

/ Recruiting临床4期IIT

GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.

In this prospective active-controlled randomized trial the investigators will assess for the first time ever the different local treatments of vulvovaginal atrophy in breast cancer patients on endocrine therapy. These patients are currently inadequately treated based on ignorance of possible treatment modalities and stigmatization of vulvovaginal atrophy.

开始日期2022-03-21

申办/合作机构

Ghent University Hospital

[+1]

100 项与脱氢表雄酮相关的临床结果

登录后查看更多信息

100 项与脱氢表雄酮相关的转化医学

登录后查看更多信息

100 项与脱氢表雄酮相关的专利（医药）

登录后查看更多信息

8,682

项与脱氢表雄酮相关的文献（医药）

2025-03-01·BONE

Hormones synthesized by the adrenal reticulum protect bone density in premenopausal women with Cushing syndrome

Article

作者: Sang, Hequn ; Wu, Keyang ; Chang, Lina ; He, Qing ; Liu, Ming ; Ye, Yuanyuan ; Li, Shuo ; Ding, Li ; Yuan, Hengjie ; Gu, Yian ; Wan, Jieying ; Yan, Siyu

BACKGROUND:

Differences in bone metabolism between patients with adrenal Cushing's syndrome (ACS) and Cushing's disease (CD) have been noted, but the impact of steroid hormones on bone metabolism remains underexplored. The purpose of this study is to explore the differences in bone metabolism between the two subtypes of Cushing's syndrome and the correlation between hormones synthesized by the adrenal reticulum and bone metabolism.

METHOD:

This retrospective study included 75 premenopausal women, consisting of 33 patients with CD and 42 patients with ACS. The clinical characteristics, laboratory examination and bone metabolism differences between the two groups were analyzed. Then, 16 patients with ACS and 12 patients with CD underwent comparison of blood steroid hormone levels. Additionally, the relationship between bone mineral density (BMD) values and steroid hormone variables was analyzed.

RESULTS:

The serum and urinary cortisol and serum ACTH concentrations were significantly higher in patients with CD compared to those with ACS. Conversely, lumbar and femoral BMD were lower, and osteocalcin (OC) levels were elevated in the ACS group. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEAS) had a significant positive correlation with Z-score in lumbar spine in both CD and ACS group. However, Z-score in femoral neck had a significant positive correlation with DHEA and DHEAS only in the ACS group.

CONCLUSION:

Bone loss is more pronounced in ACS than in CD, despite higher cortisol levels in CD patients. High levels of hormones synthesized by the adrenal reticulum might be protective for bone density in premenopausal women with hypercortisolism.

2025-02-01·Clinical Nutrition ESPEN

Effects of time-restricted feeding and weight-loaded swimming test on androgen levels and androgen receptor expression in orchiectomized male Wistar rats

Article

作者: Liow, Chun Hung ; Yaacob, Azhar ; Mohd Esa, Norhaizan ; Abu Saad, Hazizi

BACKGROUND & AIMS:

Testosterone, vital for reproductive health and muscle development, declines with age, increasing susceptibility to conditions like diabetes, obesity and sarcopenia. Conventional hormone therapy carries risks, including elevated prostate-specific antigens and prostate cancer risk, prompting exploration of safer options like intermittent fasting (IF) and physical training (PT) which potentially boost androgen in certain cases. However, their combined impacts on testosterone remain underexplored. This study aimed to assess the individual and combined effects of IF and PT on androgen and androgen receptor (AR) levels.

METHODS:

Forty male Wistar rats were divided into five groups (n = 8 each): negative control (NC) receiving food ad libitum without orchiectomized, positive control (PC) receiving daily testosterone enanthate injections, IF with 16/8 time-restricted feeding, PT with 1-h forced swimming sessions, and combined IF + PT. After 8 weeks, DHEA and testosterone levels, AR expression, gastrocnemius muscle histology, and body weight were assessed.

RESULTS:

In comparison to the NC group (429.40 ± 26.86 g), body weight in the IF (348.90 ± 15.94 g, PT (391.40 ± 16.35 g), and IF + PT groups, (360.90 ± 29.90 g) was significantly lowered (p < 0.05) after 8 weeks of study. The muscle fiber cross-sectional area in the IF (2968 μm²; IQR 1995-4053 μm²), PT (2956 μm²; IQR 2089-4371 μm²), and IF + PT groups, (3389 μm²; IQR 2260-4596 μm²) was significantly greater than the NC group (2508 μm²; IQR 1800-3567 μm². p < 0.05) after the study. DHEA levels significantly increased in the PT and IF + PT groups (375.01 ± 32.55 ng/μL and 420.00 ± 24.50 ng/μL, respectively) compared to the NC group (257.09 ± 67.79 ng/μL, p < 0.05). However, neither IF nor PT, alone or in combination, resulted in improvements in testosterone levels or AR expression in the gastrocnemius muscle. with testosterone levels remained unchanged.

CONCLUSION:

IF, PT, and IF + PT demonstrated potential effects on improving androgen levels, managing weight, and enhancing muscle growth, with IF + PT emerging as the most effective intervention. Despite these positive outcomes, the lack of impact on AR expression and testosterone levels suggests the need for further research to elucidate the underlying mechanisms and potential clinical applications for managing androgen deficiency through these interventions.

2025-02-01·TISSUE & CELL

NOX4 deficiency improves the impaired viability, inhibited the apoptosis and suppressed autophagy of DHEA-treated ovarian granulosa cells through inhibiting endoplasmic reticulum stress via inactivating PERK/ATF4 pathway

Article

作者: Wu, Lingyuan ; Xing, Xin ; Yu, Na

BACKGROUND:

PCOS is the most prevalent endocrine and metabolic problem in women of reproductive age. This current study was formulated to thoroughly expound the ovary-protecting effects of NOX4 deficiency in PCOS and probe into the intrinsic mechanisms underlying the protective effects of NOX4 deficiency against DHEA injury in ovarian GCs.

METHODS:

KGN cells were subjected to 20 nM DHEA for 48 h to establish PCOS cellular model. For loss-of-function experiments, KGN cells were transfected with si-NOX4. In addition, to investigate the biological roles of ERS and PERK/ATF4 pathway in the ovary-protecting effects of NOX4 deficiency in DHEA-treated ovarian GCs, KGN cells were pretreated with ERS agonist TM or PERK agonist CCT020312.

RESULTS:

NOX4 was highly expressed in DHEA-treated ovarian GCs. NOX4 deficiency improved the impaired viability, inhibited the apoptosis and suppressed autophagy of DHEA-treated ovarian GCs. Besides, NOX4 deficiency inactivated PERK/ATF4 pathway in DHEA-treated ovarian GCs. NOX4 deficiency repressed DHEA-induced ERS of ovarian GCs through inactivating PERK/ATF4 pathway. Pretreatment with ERS agonist TM or pretreatment with PERK agonist CCT020312 can both reduced the viability, promoted the apoptosis and strengthened autophagy of ovarian GCs, partially abolishing the ovary-protecting effects of NOX4 deficiency in DHEA-treated ovarian GCs. In general, NOX4 deficiency could improve the impaired viability, inhibited the apoptosis and suppressed autophagy of DHEA-treated ovarian GCs through repressing ERS depending on inactivation of PERK/ATF4 pathway.

CONCLUSION:

To conclude, downregulation of NOX4 could exert ovary-protecting effects in DHEA-induced PCOS cellular model through repressing ERS via inactivating PERK/ATF4 pathway.

项与脱氢表雄酮相关的新闻（医药）

2024-11-14

·国际糖尿病idiabetes

CDS2024 | 二甲双胍“跨界”频频出圈，一起追溯它的降糖外探索之旅！

CDS微专辑扫描二维码可查看更多内容编者按提起二甲双胍，了解糖尿病的人们都不陌生，除了作为60余年临床使用的降糖药，其因不断发现的诸多降糖外获益而被冠以“跨界神药”的美名。那么，二甲双胍都进行了哪些降糖外的积极探索？正在召开的中华医学会糖尿病学分会第二十六次学术会议（CDS2024）上，浙江大学医学院附属邵逸夫医院周嘉强教授带领大家一起踏上了二甲双胍的跨界之旅，重点介绍其抗肿瘤和抗衰老相关研究证据。为什么要探寻二甲双胍的降糖外获益？随着生活质量和医疗水平的提高，全球人口寿命不断延长，预估2050年60岁以上人口将增加1倍[1]。这一变化将增加老年人中年龄相关疾病的发生，尤其是慢性疾病。对于糖尿病来说，其传统并发症已被熟知，但随着糖尿病治疗进步和预期寿命延长，一些新兴并发症涌现，如肿瘤、认知功能障碍、功能性残疾、情感障碍、肝病、感染等[2]。二甲双胍在预防/治疗糖尿病新兴并发症方面的积极探索，与美国《21世纪治疗法案》支持通过观察性研究评估现有药物在其他适应证中的有效性不谋而合[3]。21世纪初，美国国立卫生研究院的研究确定，二甲双胍可以延长实验小鼠的寿命；此后不久，观察性研究发现，二甲双胍可以降低人类癌症等衰老相关疾病的发病率和死亡率；二甲双胍可使秀丽隐杆线虫寿命延长50%，这一发现使基因解析二甲双胍延长寿命的必要通路成为可能（图1）[4]。图1. 二甲双胍治疗糖尿病和衰老相关疾病的重要事件二甲双胍抗肿瘤：从预防到治疗 1 预防发生 2005年，苏格兰初步病例-对照研究首次发现，二甲双胍与2型糖尿病（T2DM）患者的肿瘤风险降低相关，并呈剂量-反应关系（图2）[5]。韩国回顾性队列研究进一步发现，在105 763例T2DM患者中，无论与未接受药物治疗还是接受非二甲双胍单药治疗相比，二甲双胍单药或联合治疗的癌症风险均更低。与未接受药物治疗者相比，二甲双胍单药治疗、二甲双胍联合治疗和非二甲双胍单药治疗者的癌症风险分别降低34%、25%和18%[6]。图2. 二甲双胍与T2DM患者肿瘤风险降低相关针对166项研究的系统回顾和荟萃分析显示，在病例对照研究和前瞻性队列研究中，使用二甲双胍的总体癌症风险分别下降45%和35%，提示二甲双胍可能对癌症发生具有普遍预防作用；针对特定癌症类型的分析表明，二甲双胍与胃肠道（RR=0.79）、泌尿系统（RR=0.88）、血液系统（RR=0.87）癌症风险降低有关[7]。另有韩国研究发现，与未使用二甲双胍的T2DM患者相比，二甲双胍治疗患者的结直肠癌发病率显著降低42%[8]。 2 改善预后二甲双胍还被证实能够改善癌症患者预后，比如降低死亡风险、延缓肿瘤转移、延长生存期。一项研究纳入2003~2018年美国国家健康和营养调查数据中3995例癌症幸存者，其中448例报告使用二甲双胍。多变量模型显示，二甲双胍的使用与全因死亡（HR=0.62）和心血管代谢死亡（HR=0.65）的风险降低显著相关[9]。中国研究人员针对139例T2DM（46例接受二甲双胍治疗）合并胰腺导管腺癌患者（103例SMAD4表达缺失/缺陷，36例表达阳性）的研究发现，二甲双胍能够减少SMAD4缺陷型胰腺导管腺癌的进展转移，提高患者生存率（图3）[10]。荷兰PREOPANC试验事后分析显示，在接受前期手术治疗的胰腺导管腺癌患者中，与未使用二甲双胍者相比，使用二甲双胍者的中位总生存期（OS）更长（29个月 vs. 14个月），无进展生存期（PFS）更久；转录组学数据表明，二甲双胍使用者低表达肿瘤免疫相关基因，促瘤M2巨噬细胞的丰度和活性降低，肿瘤溶解型树突状细胞（DCs）的募集和功能增加，有利于抗肿瘤免疫[11]。图3. 二甲双胍治疗可以抑制SMAD4缺陷型胰腺癌转移 3 机制探讨二甲双胍对肿瘤细胞的影响涉及胰岛素依赖途径的间接调节，以及通过胰岛素非依赖途径的直接作用（图4）[12]：①间接途径：二甲双胍降低血糖和血中胰岛素水平，从而降低胰岛素介导的肿瘤细胞生长和进展；②直接途径：二甲双胍通过AMPK依赖和非依赖性作用；二甲双胍诱导抑制mTORC1通路，而该通路涉及细胞过程中必不可少的蛋白复合物，包括蛋白合成和细胞增殖，这种复合物也促进了肿瘤细胞对治疗的耐药性。图4. 二甲双胍通过直接或间接途径抑制肿瘤细胞生长和延缓进展二甲双胍抗衰老：改善认知，延长寿命 1 改善认知悉尼记忆与衰老研究前瞻性纳入1037例年龄70~90岁且无痴呆的受试者，其中123例患糖尿病，67例接受二甲双胍治疗。结果发现，服用二甲双胍的T2DM患者认知功能衰退更慢，痴呆发生风险更低（图5）[13]。涵盖中国台湾14 558例受试者的回顾性队列研究也发现，二甲双胍能够显著降低老年T2DM患者痴呆风险达64%，且风险降幅呈剂量依赖性[14]。另一项回顾性队列研究纳入1393例基线有T2DM且认知功能正常的参与者，其中104例在中位4年随访期间发展为痴呆。结果显示，二甲双胍能够降低总体人群痴呆风险且在不同亚组之间存在异质性[15]。图5. 服用二甲双胍的T2DM患者认知功能衰退更慢，痴呆发生风险更低二甲双胍亦可对痴呆症最常见类型——阿尔茨海默病（AD）产生影响。一项研究采用ADNI研究数据，纳入810例AD引起轻度认知障碍（MCI）患者，其中55例基线时接受二甲双胍治疗。结果发现，二甲双胍能够改善有早期AD症状的T2DM患者认知功能[16]。另一项嵌套病例对照研究显示，服用二甲双胍≥10年的糖尿病患者与AD风险降低15%有关，累积服用量较大者风险较低，每天服用2000 mg与风险降低11%有关，提示长期高剂量使用二甲双胍与T2DM患者AD发病风险降低相关[17]。 2 延长寿命及生物学年龄一项研究使用英国临床实践研究数据链（CPRD）2000年以来的回顾性观察性数据，纳入78 241例二甲双胍单药治疗患者，12 222例磺脲类单药治疗患者以及90 463例无糖尿病对照者，所有患者至少接受180天治疗。结果表明，服用二甲双胍的患者，不但健康状况明显更好，事件发生率更低，而且寿命甚至超过非糖尿病受试者的平均水平[18]。 2019年发表的TRIIM试验首次证实生物学年龄可逆转。该研究纳入10例51~65岁健康男性受试者，二甲双胍与生长激素、脱氢表雄酮三种药物联用1年后，人体表观遗传年龄平均下降2.5年，表观遗传时钟得以逆转[19]。无独有偶，中国科学院动物研究所及基因研究所刘光慧、张维绮和曲静教授历时8年的研究于近期发表在Cell杂志，首次证实二甲双胍能够减缓灵长类动物衰老时钟，显著降低多组织器官的DNA甲基化年龄、基因转录年龄和血浆蛋白年龄，最高可达6岁（大脑额叶），相当于将器官年龄回拨至6年前（约等于人类年龄18年）（图6）[20]。该研究率先通过二甲双胍系统降低灵长类动物的多维生物年龄，为推进对抗人类衰老的药物策略铺平了道路。图6. 二甲双胍减缓灵长类动物衰老时钟，将大脑年龄回拨至6年前 3 机制探讨 López-Otín等人提出9个衰老特征[21]，包括4个主要特征（蛋白质稳态丧失、端粒损耗、基因组不稳定性和表观遗传改变）、3个拮抗特征（营养感应失调、线粒体功能障碍和细胞衰老）和2个综合特征（细胞间通讯改变和干细胞耗竭）[22]。AMPK激活是维持细胞完整性和功能所必需的，其表达在衰老过程中下降，并影响上述衰老特征[23]。大量研究证实二甲双胍能够通过调节AMPK等信号通路，改善衰老特征，延缓衰老并对各种衰老相关疾病进展显示出保护作用（图7）[22]。图7. 二甲双胍通过调节AMPK，改善衰老特征岂止改善新兴并发症，二甲双胍更多潜在获益探索不停二甲双胍通过多靶点作用，改善糖尿病新兴并发症，除了上述抗肿瘤和抗衰老，还可抗感染、改善衰弱、预防骨关节炎、改善肝病及情感障碍等[24-29]。当然，二甲双胍潜在临床获益不止于此。比如，在诱导排卵方面，二甲双胍通过降低血浆胰岛素水平，改善胰岛素抵抗，调整月经，降低雄激素水平，提高雌二醇水平，改善多囊卵巢综合征（PCOS）患者的多毛症，使月经规律，诱导排卵，增加妊娠率[30]。在心血管疾病方面，二甲双胍通过AMPK和非AMPK靶点改善血管内皮功能，降低不良心血管事件及死亡风险[31]；UKPDS 91研究还表明，二甲双胍早期强化血糖控制可为T2DM患者带来接近终生的心血管和生存获益[32]。二甲双胍还在延长妊娠、治疗脱发等方面开展了相关研究，更多疾病领域探索不断。相信随着研究证据的积累，二甲双胍将会持续带来更多惊喜！注：目前我国尚未批准二甲双胍用于癌症、感染、肥胖、非酒精性脂肪性肝病、心衰、骨关节炎、认知障碍、衰老等疾病。参考文献（上下滑动可查看） 1. Du N, et al. Biomedicines. 2024; 12(1): 127. 2. Tomic D, et al. Nat Rev Endocrinol. 2022; 18(9): 525-539. 3. Yu OHY, Suissa S. Diabetes Care. 2023; 46(5): 904-912. 4. Soukas AA, et al. Trends Endocrinol Metab. 2019; 30(10): 745-755. 5. Evans JM, et al. BMJ. 2005; 330(7503): 1304-1305. 6. Seo HJ, Oh HS. Epidemiol Health. 2021; 43: e2021103. 7. O'Connor L, et al. J Natl Cancer Inst. 2024; 116(4): 518-529. 8. Seo SI, et al. J Pers Med. 2022; 12(4): 584. 9. Li Y, et al. BMC Med. 2024; 22(1): 269. 10. Wang C, et al. Protein Cell. 2021; 12(2): 128-144. 11. van Eijck CWF, et al. J Natl Cancer Inst. 2024; 116(8): 1374-1383. 12. Galal MA, et al. Int J Mol Sci. 2024; 25(7): 4083. 13. Samaras K, et al. Diabetes Care. 2020; 43(11): 2691-2701. 14. Sun M, et al. Brain. 2024; 147(4): 1474-1482. 15. Tang H, et al. Alzheimers Dement. 2024; 20(2): 975-985. 16. Pomilio C, et al. Geroscience. 2022; 44(3): 1791-1805. 17. Sluggett JK, et al. J Clin Endocrinol Metab. 2020; 105(4): dgz234. 18. Bannister CA, et al. Diabetes Obes Metab. 2014; 16(11): 1165-1173. 19. Fahy GM, et al. Aging Cell. 2019; 18(6): e13028. 20. Yang Y, et al. Cell. 2024; 187(22): 6358-6378. e29. 21. López-Otín C, et al. Cell. 2013; 153(6): 1194-1217. 22. Chen S, et al. Theranostics. 2022; 12(6): 2722-2740. 23. Penugurti V, et al. Semin Cancer Biol. 2024; 106-107: 15-27. 24. Chow E, et al. Pharmaceuticals (Basel). 2022; 15(4): 442. 25. 韩家超, 等. 中华临床医师杂志(电子版). 2023; 17(3): 349-355. 26. Liu P, et al. Eur J Med Res. 2023; 28(1): 65. 27. Li J, et al. Ann Rheum Dis. 2020; 79(5): 635-645. 28. Baker MC, et al. JAMA Netw Open. 2023; 6(3): e233646. 29. Calkin CV, et al. J Clin Psychiatry. 2022; 83(2): 21m14022. 30. Li Y, et al. Fertil Steril. 2020; 113(1): 197-204. 31. Ding Y, et al. Theranostics. 2021; 11(19): 9376-9396. 32. Adler AI, et al. Lancet. 2024; 404(10448): 145-155. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果

2024-09-10

·drugs

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

临床结果

2024-07-19

·Outsourcing Pharma

Avista and Hamilton Lane Join Forces to Propel Growth and Innovation at Cosette Pharmaceuticals

The companies will jointly control Cosette, with a focus on accelerating innovation and growth. Since Avista's initial investment in Cosette in December 2018, Cosette has launched new products through research and development efforts, acquisitions, and licensing deals. This includes the acquisition of Ambien and Ambien CR in the United States from Sanofi US. The company reports that these initiatives have led to significant EBITDA growth and free cash flow generation, positioning Cosette for future opportunities. Apurva Saraf, president and CEO of Cosette, said: “This partnership is a testament to the remarkable transformation our business has achieved over the past four years, driven by an unwavering commitment to strategic business development and operational excellence. I am immensely proud of the entire Cosette team for their dedication in delivering this robust growth. “We have successfully diversified our portfolio with branded products such as Clomid, Ambien, and Benicar, along with innovative, patent-protected drugs like Vyleesi and Intrarosa. With our strong R&D and business development pipeline, we are well positioned to drive substantial growth in partnership with Avista and Hamilton Lane." Financial strength and future opportunities for Cosette Pharmaceuticals The companies indicate that this transaction will enhance Cosette's balance sheet and support growth through investments in R&D and strategic acquisitions. The goal is to build a durable, high-growth, branded pharmaceutical company. As part of the transaction, Cosette has also secured a new term loan financing with Hayfin Capital Management and a new revolving credit facility provided by UBS Investment Bank, Capital One, National Association, and Santander Corporate & Investment Bank, who acted as joint lead arrangers and joint bookrunners for the financing. googletag.cmd.push(function () { googletag.display('text-ad1'); }); David Burgstahler, managing partner and CEO of Avista, added: “We value Avista's long-term relationship with Hamilton Lane and look forward to collaborating with them as a strategic partner to drive growth and value at Cosette. Our collective expertise will prove invaluable as Cosette evaluates larger M&A opportunities as part of the company's growth strategy.” Cosette Pharmaceuticals has made significant contributions to the pharmaceutical industry, particularly in the realm of specialty pharmaceuticals. The company has a strong focus on developing and commercializing branded and generic products that address unmet medical needs. With a diverse portfolio that includes notable products, Cosette has demonstrated a commitment to innovation and patient care. It says its strategic approach to research and development, coupled with targeted acquisitions and licensing deals, has enabled them to introduce groundbreaking therapies and expand their market presence, positively impacting patient outcomes and advancing healthcare solutions.

并购引进/卖出

100 项与脱氢表雄酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08409	脱氢表雄酮	G03XX01 A14AA07	DB01708

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
潮热	加拿大	Endoceutics, Inc.	2019-11-06
骨质疏松症	加拿大	Endoceutics, Inc.	2019-11-06
性交困难	美国	Millicent Oy	2016-11-16
外阴和阴道萎缩	美国	Millicent Oy	2016-11-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
绝经期泌尿生殖系综合征	临床3期	美国	AMAG Pharmaceuticals, Inc.	2020-05-01
绝经期综合征	临床3期	美国	AMAG Pharmaceuticals, Inc.	2020-05-01
绝经后障碍	临床3期	美国	AMAG Pharmaceuticals, Inc.	2020-05-01
泌尿道感染	临床3期	美国	AMAG Pharmaceuticals, Inc.	2020-05-01
乳腺癌	临床3期	-	Endoceutics, Inc.	2018-11-06
乳腺癌	临床3期	-	AMAG Pharmaceuticals, Inc.	2018-11-06
克罗恩病	临床2期	美国	Inflabloc Pharmaceuticals, Inc.	2005-01-01
克罗恩病	临床2期	加拿大	Inflabloc Pharmaceuticals, Inc.	2005-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03491007 (CTgov)	临床2期	创伤后应激障碍	5	PBO (Placebo)	齋醖膚醖齋蓋廠範窪蓋(壓選鹽繭願艱糧繭衊觸) = 網遞齋獵鏇觸鹽餘遞醖鹹糧糧齋鑰願餘窪憲積 (襯鏇淵衊齋襯餘遞醖膚, 範憲獵窪衊膚餘繭餘鹹 ~ 獵夢夢範築鏇壓繭衊鑰) 更多	-	2023-05-06
				DHEA (DHEA)	醖窪鏇範鹹願觸鹹淵夢(範糧鏇網淵構簾膚鹽壓) = 齋鏇艱餘簾鬱獵簾齋艱醖鬱艱築觸願膚蓋願鑰 (鹽廠範蓋繭餘鬱獵網願, 鏇構選夢選膚築壓壓衊 ~ 襯鹽鬱網艱鏇繭淵淵糧) 更多
NCT01256671 (CTgov)	临床3期	外阴和阴道萎缩	530	DHEA (prasterone)	蓋觸鬱鹹網構獵積齋願(鑰願觸齋壓繭糧憲顧網) = 製觸襯遞齋蓋網醖鏇鏇構蓋網醖壓艱鬱膚範淵 (襯顧憲壓艱襯願願膚網, 簾鏇壓製製淵淵鹽淵選 ~ 艱鏇窪齋夢選網網襯遞) 更多	-	2017-10-18
NCT01376349 (CTgov)	临床3期	阴道排出物 \| 女性生殖器官肿瘤 \| 乳腺癌	464	prasterone (Arm I Low Dose DHEA)	鏇餘夢醖糧壓鏇鹹鹹襯(衊繭鑰構壓衊鹹範簾夢) = 齋鏇艱觸糧顧鏇鹹鏇範鑰願餘廠襯範製網夢遞 (廠窪襯衊膚壓醖襯夢襯, 範範鑰獵選夢顧憲遞淵 ~ 構餘範構餘膚淵範醖膚)	-	2017-08-25
				prasterone (Arm II High Dose DHEA)	鏇餘夢醖糧壓鏇鹹鹹襯(衊繭鑰構壓衊鹹範簾夢) = 鏇顧鑰遞齋醖醖鏇壓遞鑰願餘廠襯範製網夢遞 (廠窪襯衊膚壓醖襯夢襯, 鑰蓋憲衊構衊獵鏇製夢 ~ 夢淵糧鏇廠觸糧衊願襯)
NCT01358760 (CTgov)	临床3期	外阴和阴道萎缩	450	Placebo (Placebo)	鏇願築鬱壓製鬱觸獵齋(窪鏇願膚網鹽範糧網衊) = 糧鏇範艱膚淵鹹窪製觸構網艱艱糧簾範鹹顧製 (襯蓋餘鬱醖願範網鑰構, 餘廠憲觸觸簾繭醖積獵 ~ 淵醖衊齋鏇壓遞獵夢構) 更多	-	2017-06-12
				DHEA (0.25% DHEA)	鏇願築鬱壓製鬱觸獵齋(窪鏇願膚網鹽範糧網衊) = 鹹鹽顧糧鏇網窪繭夢襯構網艱艱糧簾範鹹顧製 (襯蓋餘鬱醖願範網鑰構, 壓繭壓鑰糧窪鑰顧選鑰 ~ 獵積網鏇積鑰糧簾積選) 更多
NCT02013544 (CTgov)	临床3期	外阴和阴道萎缩	558	Placebo	窪鹽遞築廠網構繭廠夢(衊衊夢鏇網鹹蓋廠鹽夢) = 糧廠鬱廠壓鏇鏇醖窪鬱簾蓋鏇製鬱範鑰選積繭 (憲鹽壓願鬱餘鹽範廠廠, 鏇觸獵簾壓鬱夢顧鹹廠 ~ 鏇鏇獵齋蓋遞顧淵鬱蓋) 更多	-	2017-06-01
NCT01846442 (CTgov)	临床3期	外阴和阴道萎缩	218	Placebo (Placebo)	廠衊襯鏇製窪觸構製憲(蓋糧衊襯築遞鬱範襯願) = 構夢艱蓋憲獵蓋觸夢廠淵網製網獵襯鑰壓選構 (觸壓積襯顧觸築網觸淵, 夢積膚積選餘醖觸廠構 ~ 憲夢鹹製鬱簾構憲廠夢) 更多	-	2017-04-28
				DHEA (0.25%) (0.25% DHEA)	廠衊襯鏇製窪觸構製憲(蓋糧衊襯築遞鬱範襯願) = 膚蓋遞築齋襯夢鬱鬱醖淵網製網獵襯鑰壓選構 (觸壓積襯顧觸築網觸淵, 醖衊糧構範壓鬱獵鏇糧 ~ 選鏇襯築製餘襯窪顧選) 更多
NCT01256684 (CTgov)	临床3期	外阴和阴道萎缩	255	Placebo (Placebo)	壓鹹顧鹹鹽鑰範顧糧範(鬱窪簾網積餘餘膚鏇鬱) = 範網鹽觸鹽襯簾襯築選壓構鹽鏇範顧鹽憲網淵 (網齋糧膚憲觸範製鏇夢, 選獵觸選選鑰鹹蓋窪衊 ~ 鬱醖襯餘餘膚願淵顧遞) 更多	-	2017-04-25
				DHEA (0.25% DHEA)	壓鹹顧鹹鹽鑰範顧糧範(鬱窪簾網積餘餘膚鏇鬱) = 遞範網艱築鹽糧淵齋憲壓構鹽鏇範顧鹽憲網淵 (網齋糧膚憲觸範製鏇夢, 築鏇願襯廠鬱積膚築鹹 ~ 鏇鹽簾鏇淵壓鬱餘膚範) 更多
NCT01256671 (Pubmed \| Maturitas) 人工标引	临床3期	外阴和阴道萎缩	521	Prasterone	鏇鏇獵淵構網憲膚廠醖(夢簾衊醖醖糧窪網淵鹹) = similar improvement results on vaginal dryness and irritation/itching. Highly significant beneficial effects (p<0.0001 versus baseline for all) at gynecological examination on vaginal secretions, color, epithelial integrity and epithelial surface thickness 觸蓋憲鹽膚選膚構選簾 (製遞艱遞簾鬱膚衊蓋膚 ) 更多	积极	2015-05-01
NCT02150330 (Pubmed \| Taiwan J Obstet Gynecol)	临床3期	卵巢疾病	10	DHEA supplementation	醖齋廠簾鹽鑰衊夢夢鑰(壓選繭淵鑰構製壓顧壓) = 膚糧壓鏇積膚糧壓網糧壓淵製餘構選簾餘憲淵 (築醖蓋夢選鹹構鬱衊鏇 )	-	2015-04-01
NCT01358760 (Pubmed \| Climacteric) 人工标引	临床3期	外阴和阴道萎缩	-	dehydroepiandrosterone	糧網構壓簾鹽獵艱鹹獵(膚窪窪獵範衊積獵觸積) = In parallel, the statistical significance over placebo (p value) on MBS vaginal dryness at 6 weeks was 0.09 followed by an increase to 0.198 at 12 weeks. 膚壓積餘艱觸衊衊選鑰 (淵鏇憲鬱鬱積憲繭窪遞 ) 更多	不佳	2015-01-01
				Placebo